Publications by authors named "F Pitoiset"
Article Synopsis
- A study examined low-dose interleukin-2 (IL-2) as a treatment for 13 different autoimmune diseases, focusing on its ability to activate regulatory T cells (Tregs) which are crucial in managing these conditions.
- 81 patients received IL-2 over a span of treatment, resulting in significant Treg expansion and activation, with clinical improvements noted in the majority of the diseases assessed, particularly in conditions like ankylosing spondylitis and systemic lupus erythematosus.
- The findings suggest that IL-2 is well-tolerated and effective at targeting Tregs, indicating its potential as a valuable addition to future therapeutic strategies for autoimmune diseases.
Article Synopsis
- McGonagle and McDermott propose a classification of autoimmune and autoinflammatory diseases as a continuum, highlighting the interplay between purely autoimmune, purely autoinflammatory, and mixed disease types based on genetic associations.
- Researchers analyzed blood samples from 443 patients with 15 different autoimmune or autoinflammatory diseases and 71 healthy individuals, utilizing deep immunophenotyping to identify immune cell populations through various flow cytometry techniques.
- Findings revealed five disease clusters based on immune cell characteristics, linked to inflammation levels and affected tissues, with implications for better defining targeted therapies and warranting further research into specific immune cell interactions.
Mucosal surfaces serve as the primary entry points for pathogens such as SARS- CoV-2 coronavirus or HIV in the human body. Mucosal vaccination plays a crucial role to successfully induce long-lasting systemic and local immune responses to confer sterilizing immunity. However, antigen formulations and delivery methods must be properly selected since they are decisive for the quality and the magnitude of the elicited immune responses in mucosa.
View Article and Find Full Text PDFBackground: Multiple sclerosis (MS) is associated with regulatory T cells (Tregs) insufficiency while low-dose interleukin-2 (IL2) activates Tregs and reduces disease activity in autoimmune diseases.
Methods: We aimed at addressing whether IL2 improved Tregs from MS patients. MS-IL2 was a single-center double-blind phase-2 study.
Objectives: A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a multicentre, double-blinded, randomised, placebo-controlled phase II proof-of-concept trial to evaluate the efficacy of low-dose IL-2 therapy in patients with SLE having moderate-to-severe disease activity while receiving standard treatment.
Methods: We randomly assigned 100 patients in a 1:1 ratio to receive either 1.